Publikationen, an denen er mitarbeitet Rafael León Martínez (21)

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

2019

  1. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux

    Journal of Pineal Research, Vol. 67, Núm. 1

2018

  1. The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca 2+ dysregulation, and mitochondrial abnormalities

    Journal of Neurochemistry, Vol. 145, Núm. 2, pp. 170-182

2017

  1. Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia"

    ACS chemical neuroscience, Vol. 8, Núm. 1, pp. 210

  2. ConBr, A Lectin Purified from the Seeds of Canavalia brasiliensis, Protects Against Ischemia in Organotypic Culture of Rat Hippocampus: Potential Implication of Voltage-Gated Calcium Channels

    Neurochemical Research, Vol. 42, Núm. 2, pp. 347-359

  3. Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease

    Scientific Reports, Vol. 7

  4. ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia

    ACS Chemical Neuroscience, Vol. 8, Núm. 1, pp. 67-81

  5. Inclusion complex of ITH12674 with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization and pharmacological effect

    Carbohydrate Polymers, Vol. 157, pp. 94-104

  6. Novel multitarget hybrid compounds for the treatment of alzheimer’s disease

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 9, pp. 1027-1043

  7. Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices

    Neuropharmacology, Vol. 116, pp. 110-121

2016

  1. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases

    Pharmacology and Therapeutics, Vol. 157, pp. 84-104

  2. Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures

    Molecular Neurobiology, Vol. 53, Núm. 5, pp. 3338-3348

  3. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators

    Journal of Medicinal Chemistry, Vol. 59, Núm. 21, pp. 9967-9973

2015

  1. Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase i induction

    Biochemical Pharmacology, Vol. 97, Núm. 4, pp. 473-481

  2. Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection

    Biochemical Pharmacology, Vol. 97, Núm. 4, pp. 463-472

  3. Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a 'drug-prodrug' mechanism of action

    British Journal of Pharmacology, Vol. 172, Núm. 7, pp. 1807-1821

  4. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models

    Neuropharmacology, Vol. 99, pp. 187-195

  5. New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection

    Future Medicinal Chemistry, Vol. 7, Núm. 15, pp. 1961-1969

  6. The melatonin- N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction

    ACS Chemical Neuroscience, Vol. 6, Núm. 2, pp. 288-296